Skip to main content
Top
Published in: BMC Psychiatry 1/2021

Open Access 01-12-2021 | Schizophrenia | Case report

Caffeine-clozapine interaction associated with severe toxicity and multiorgan system failure: a case report

Authors: Alex Yartsev, Carmelle Peisah

Published in: BMC Psychiatry | Issue 1/2021

Login to get access

Abstract

Background

Caffeine is a known inhibitor of Clozapine metabolism mediated by inhibition of CYP1A2. Hitherto, the effects of caffeine on Clozapine levels have always been modest, as have the clinical manifestations of toxicity resulting from their interaction. We present a case of severe toxicity associated with the co-consumption of caffeine and Clozapine culminating in life-threatening complications requiring management in Intensive Care.

Case presentation

A 34 year old male with a history of chronic schizophrenia, who had been managed stably on 400 mg Clozapine for the previous 5 years, changed his dietary behaviour and began consuming caffeine-containing energy drinks over the course of 3 weeks. The total daily dose of caffeine was estimated as 600 mg/day (four cans of Red Bull). He subsequently presented to the Emergency Department with life-threatening Clozapine toxicity, resulting in a decreased level of consciousness, severe metabolic acidosis, acute respiratory failure, raised inflammatory markers and acute renal failure attributed to interstitial nephritis. Maximum recorded Clozapine level was 1796 ng/ml.

Conclusions

This case describes the interaction between a common caffeine-containing beverage and a commonly prescribed antipsychotic medication, associated with severe adverse effects. We call for clinical and scientific attention to the possible interaction between these substances and draw attention to the implications for prescribing practices and patient counselling.
Literature
3.
4.
go back to reference Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995;272(3):984–90.PubMed Pirmohamed M, Williams D, Madden S, Templeton E, Park BK. Metabolism and bioactivation of clozapine by human liver in vitro. J Pharmacol Exp Ther. 1995;272(3):984–90.PubMed
6.
go back to reference Odom-White A, de Leon J. Clozapine levels and caffeine. J Clin Psychiatry. 1996;57(4):175–6.PubMed Odom-White A, de Leon J. Clozapine levels and caffeine. J Clin Psychiatry. 1996;57(4):175–6.PubMed
11.
go back to reference Cerimele JM, Stern AP, Jutras-Aswad D. Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia. Am J Psychiatry. 2010;167(3):353.CrossRef Cerimele JM, Stern AP, Jutras-Aswad D. Psychosis following excessive ingestion of energy drinks in a patient with schizophrenia. Am J Psychiatry. 2010;167(3):353.CrossRef
17.
go back to reference Štuhec M. Clozapine-induced elevated C-reactive protein and fever mimic infection. Gen Hosp Psychiatry. 2013;35(6):680–e5.PubMed Štuhec M. Clozapine-induced elevated C-reactive protein and fever mimic infection. Gen Hosp Psychiatry. 2013;35(6):680–e5.PubMed
18.
go back to reference Duarte TA, Godinho FD, Ferreira AL, Simões do Couto F, Martins PT. Clozapine-Induced Procalcitonin Elevation. Prim Care Companion CNS Disord. 2017;19(3). Duarte TA, Godinho FD, Ferreira AL, Simões do Couto F, Martins PT. Clozapine-Induced Procalcitonin Elevation. Prim Care Companion CNS Disord. 2017;19(3).
19.
go back to reference Cohen D, Correll CU. Second-Generation Antipsychotic-Associated Diabetes Mellitus and Diabetic Ketoacidosis: Mechanisms, Predictors, and Screening Need (ASCP Corner). J Clin Psychiatry. 2009;70(5):765.CrossRef Cohen D, Correll CU. Second-Generation Antipsychotic-Associated Diabetes Mellitus and Diabetic Ketoacidosis: Mechanisms, Predictors, and Screening Need (ASCP Corner). J Clin Psychiatry. 2009;70(5):765.CrossRef
Metadata
Title
Caffeine-clozapine interaction associated with severe toxicity and multiorgan system failure: a case report
Authors
Alex Yartsev
Carmelle Peisah
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2021
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/s12888-021-03199-x

Other articles of this Issue 1/2021

BMC Psychiatry 1/2021 Go to the issue